Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10

References

• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison L, Bennett N, Reingold A, Thomas A, Schaffner W, Craig A, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41. doi:10.1086/648599.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):1–20. doi:10.1371/journal.pone.0177113.
   Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MPME. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:629. doi:10.1016/S1473-3099(15)70044-7.
   PubMed Web of Science ®Google Scholar
• Ricketson LJ, Conradi NG, Vanderkooi OG, Kellner JD. Changes in the nature and severity of invasive pneumococcal disease in children before and after the seven-valent and thirteen-valent pneumococcal conjugate vaccine programs in Calgary, Canada. Pediatr Infect Dis J. 2018;37(1):22–27. doi:10.1097/INF.0000000000001709.
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, David E, McIntosh RRR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197–209. doi:10.1016/j.ijid.2009.05.010.
   PubMed Web of Science ®Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Heal. 2018;6(7):e744–57. doi:10.1016/S2214-109X(18)30247-X.
   PubMed Web of Science ®Google Scholar
• Weinberger MD, Malley R, Lipsitch M. Serotype replacement in disease following pneumococcal vaccination: A discussion of the evidence. NIH Public Access. 2011;378:1962–73.
   Google Scholar
• Kaplan SL, Barson WJ, Lin PL, Stovall SH, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429–36. doi:10.1542/peds.2008-1702.
   PubMed Web of Science ®Google Scholar
• Eun HC, So HK, Byung WE, Sun JK, Nam HK, Lee J, Lee HJ. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis. 2008;14(2):275–81. doi:10.3201/eid1402.070807.
   PubMed Web of Science ®Google Scholar
• Ministerio de la Protección Social.Lineamientos Técnicos y Operativos para la Universalización de la Vacuna Contra el Neumococo en el Esquema del Programa Ampliado de Inmunizaciones Colombia 2011. Minist Protección Soc [Internet]. 2011;(32):1–39. [accessed 2017 Aug 10]. www.dssa.gov.co/index.php/descargas/411-lin/file
   Google Scholar
• Ministerio de Salud de Colombia. Coberturas de vacunación municipal por biológicos - diciembre 2016 [Internet]; 2017. [accessed 2017 Oct 7]. www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/pai.aspx
   Google Scholar
• Ricketson LJ, Vanderkooi OG, Wood ML, Leal J, Kellner JD. Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta. Can J Infect Dis Med Microbiol. 2014;25(2):71–75. doi:10.1155/2014/196748.
   PubMed Web of Science ®Google Scholar
• Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines Internet. 2017;16(10):1007–27. doi:10.1080/14760584.2017.1362339.
   PubMed Web of Science ®Google Scholar
• Avila-Aguero ML, Ulloa-Gutierrez R, Falleiros-Arlant LHPO. Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 simi-lar in terms of protection against serotype 19A? Expert Rev Vaccines. 2017;16:1–4. doi:10.1080/14760584.2017.1334555.
   PubMed Web of Science ®Google Scholar
• Cassiolato AP, Grassi Almeida SC, Andrade AL, Minamisava R, Cristina de Cunto Brandileone M. Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLoS One. 2018;13(11):1–13. doi:10.1371/journal.pone.0208211.
   Web of Science ®Google Scholar
• Muñoz A, Véliz L, Moreno G, Escobar C, Cerda J, Fica A, Moreno G, Muñoz A, Véliz L. Opinión del Comité Consultivo de Inmunizaciones Sociedad Chilena de Infectología: vacuna neumocóccica conjugada en niños y la emergencia de serotipo 19A. Rev Chil Infectología. 2016;33(3):304–06. doi:10.4067/S0716-10182016000300009.
   PubMedGoogle Scholar
• Castañeda E, Agudelo CI, De Antonio R, Rosselli D, Calderón C, Ortega-Barria E. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010. BMC Infect Dis. 2012;12:124.
   PubMed Web of Science ®Google Scholar
• Agudelo CI, De Antonio RCE. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010–2015: a sistematic review and a time series analysis. Vaccine. 2018;36:4861–74. doi:10.1016/j.vaccine.2018.06.068.
   PubMed Web of Science ®Google Scholar
• Leal AL, Montañez AM, Buitrago G, Patiño J, Camacho G, Moreno VM. Impact of ten-valent pneumococcal conjugate vaccine introduction on serotype distribution trends in Colombia: an interrupted time-series analysisMarch 2019 poster abstracts • OFID 2017. Open Forum Infect Dis. 2017;4(Suppl1):S463. 4 (Suppl 1) S531. doi:10.1093/ofid/ofx163.1182.
   Google Scholar
• Ramos V, Parra EL, Duarte C, Moreno J. Characterization of Streptococcus pneumoniae invasive serotype 19A isolates recovered in Colombia. Vaccine [Internet]. 2014;32(7):755–58. doi:10.1016/j.vaccine.2013.12.024.
   PubMed Web of Science ®Google Scholar
• Departamento Nacional de Estadistica (DANE). Informe Censo Nacional de Población y vivienda. 2018 Colombia [Internet]; 2018.  [accessed 2019 Apr 10]. http://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/censo-nacional-de-poblacion-y-vivenda-2018
   Google Scholar
• Gagetti P, Faccone D, Reijtman V, Fossati S, Rodriguez M, Veliz O, Ceriana P, Regueira M, Corso A. Characterization of Streptococcus pneumoniae invasive serotype 19A isolates from Argentina (1993–2014). Vaccine Internet. 2017;35(35):4548–53. doi:10.1016/j.vaccine.2017.07.030.
   PubMed Web of Science ®Google Scholar
• Secretaria do Estado da Saúde (São Paulo). 2016. Coordenadoria de Controle de Doenças. Instituto Adolfo Lutz. Informação da vigilância das pneumonias e meningites bacterianas: sireva II [Internet]. p. 43. [accessed 2017 Nov 20]. www.ial.sp.gov.br/ial/publicacoes/boletins
   Google Scholar
• Instituto de Salud Pública. Ministerio de Salud de Chile. Vigilancia de laboratorio de Streptococcus pneumoniae procedente de enfermedad invasora, Chile 2011–2017; 2017(7):1–15. [accessed 2017 Nov 10]. www.ispch.cl/content/27521..
   Google Scholar
• Dirección de Redes en Salud Pública. Subdirección Laboratorio Nacional de Referencia, Grupo de Microbiología. Instituto Nacional de Salud de Colombia. Vigilancia por Laboratorio de aislamientos invasores de Streptococcus pneumoniae Colombia 2006–2017 [Internet]. 2018. 1–[accessed 2018 May 8]. www.ins.gov.co/buscador-even-tos/Informacin de laboratorio/Vigilancia por Laboratorio de S pneumoniae 2006-2017.pdf
   Google Scholar
• Brandileone MCC, Almeida SCG, Minamisava R, Andrade AL. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine [Internet]. 2018;36(19):2559–66. doi:10.1016/j.vaccine.2018.04.010.
   PubMed Web of Science ®Google Scholar
• Olarte L, Barson WJ, Barson R, Lin PL, Romero JR, Tan TQ, Givner LB, Bradley JS, Hoffman JA, Hultén KG, et al. Impact of the 13 valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children. Clin Infect Dis. 2015;61:767–75. doi:10.1093/cid/civ368.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJLP, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO. Early trends for invasive pneumococcal infections in children after the introduction of the 13 valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32:203–07. doi:10.1097/INF.0b013e318275614b.
   PubMed Web of Science ®Google Scholar
• Iroh Tam PY, Madoff LC, Combes B, Pelton SI. Invasive pneumococcal disease after implementation of 13 valent conjugate vaccine. Pediatrics. 2014;134:210–17. doi:10.1542/peds.2014-0473.
   PubMed Web of Science ®Google Scholar
• Moore MR, Linl-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13 valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–09. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Moore MR, Linl-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, et al. Effectiveness of 13 valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case control study. Lancet Respir Med. 2016;4:399–406. doi:10.1016/S2213-2600(16)00052-7.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MPME. Serotype specific effectiveness and correlates of protection for the 13 valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2015;15:535–43. doi:10.1016/S1473-3099(15)70044-7.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli. Vaccine. 2014;32:3452–59. doi:10.1016/j.vaccine.2014.03.065.
   PubMed Web of Science ®Google Scholar
• Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, García-de-Miguel M-J, Hernández-Sampelayo T, Otheo E, Méndez C. Expansion of serotype coverage in the universal pediatric vaccination calendar: short term effects on age-and serotype dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Clin Vaccine Immnunol. 2013;20:1524–30. doi:10.1128/CVI.00239-13.
   PubMed Web of Science ®Google Scholar
• Moore MR, Gertz RE Jr, Woodbury RL, Barkocy‐Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison L, et al. Population snapshot of emergent streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016–27. doi:10.1086/588418.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Collins S, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis [Internet]. 2018;18(4):441–51. doi:10.1016/S1473-3099(18)30052-5.
   PubMed Web of Science ®Google Scholar
• Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother. 2009;64(3):507–10. doi:10.1093/jac/dkp210.
   PubMed Web of Science ®Google Scholar
• Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28(26):4249–59. doi:10.1016/j.vaccine.2010.04.020.
   PubMed Web of Science ®Google Scholar
• Camacho-badilla K, Falleiros-arlant LH, Brea J, Avila-aguero ML. Challenges in the surveillance of invasive pneumococcal disease in the postvaccination era. J Pediatric Infect Dis Soc. 2015;4(2):91–93. doi:10.1093/jpids/piv025.
   PubMed Web of Science ®Google Scholar
• Olarte L, Romero J, Barson W, Bradley J, Lin PL, Givner L, Tan T, Hoffman J, Hultén KG, Mason EO, et al. Osteoarticular infections caused by streptococcus pneumoniae in children in the post pneumococcal conjugate vaccine era. Pediatr Infect Dis J. 2017;36:1201–04. doi:10.1097/INF.0000000000001697.
   PubMed Web of Science ®Google Scholar
• Setchanova L, Alexandrova A, Pencheva D, Sirakov I, Mihova K, Kaneva R, Setchanova L, Mitov I. Rise of multidrug-resistant Streptococcus pneumoniae clones expressing non-vaccine serotypes among children following introduction of the 10-valent pneumococcal conjugate vaccine in Bulgaria. J Glob Antimicrob Resist. 2018;15:6–11. Internet. doi:10.1016/j.jgar.2018.05.012.
   PubMed Web of Science ®Google Scholar
• Rojas JP, Leal AL, Patinõ J, Montañez A, Camacho G, Beltrán S, Bonilla C, Barrero R, Mariño C, Ramos N, et al. Caracterización de pacientes fallecidos por enfermedad neumocóccica invasiva en la poblacion infantil de Bogotá, Colombia. Rev Chil Pediatr. 2016;87(1):48–52. doi:10.1016/j.rchipe.2015.10.005.
   PubMedGoogle Scholar
• WHO. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Wkly Epidemiol Rec [Internet]. 2019;94(8):85–104. [accessed 2019 Jun 10]. http://orton.catie.ac.cr/cgi-bin/wxis.exe/?IsisScript=KARDEX.xis&method=post&formato=2&cantidad=1&expresion=mfn=003687 https://apps.who.int/iris/bitstream/handle/10665/310968/WER9408.pdf?ua=1
   Google Scholar